Navigation Links
Group of anti-diabetic drugs can significantly lower cancer risk in women with type 2 diabetes
Date:12/5/2013

Thursday, Dec. 5, 2013, Cleveland: A Cleveland Clinic-led study shows that a specific type of diabetes drug can decrease the risk of cancer in female patients with type 2 diabetes by up to 32 percent.

People with type 2 diabetes have a higher rate of cancer development and recurrence compared to the general population. This study published online today by the journal Diabetes, Obesity and Metabolism shows that widely prescribed anti-diabetes drugs can be linked to either an increased or decreased risk of cancer, depending on the type of medication prescribed.

A team of researchers led by Sangeeta Kashyap, M.D., an endocrinologist and associate professor of medicine at Cleveland Clinic's Endocrinology & Metabolism Institute, compared two groups of drugs commonly used to treat type 2 diabetes insulin sensitizers and insulin secretagogues. Insulin sensitizers lower blood sugar and insulin levels in the body by increasing the muscle, fat and liver's response to insulin. Insulin secretagogues lower blood sugar by stimulating pancreatic beta cells to make more insulin.

"What this study shows us is that using insulin secretagogues to increase insulin production correlates with an increased cancer risk in women with type 2 diabetes," said Kashyap. "By contrast, insulin sensitizers cut insulin levels and can decrease cancer growth. So, clearly, when prescribing anti-diabetic medications, it's important to consider the impact a drug has on fueling cancer growth."

In a retrospective analysis, researchers cross-indexed the electronic health record-based Cleveland Clinic Diabetes Registry (25,613 patients) with the histology-based tumor registry (48,051 cancer occurrences) over an 8-year period (19982006). More than 890 incident cancer cases were identified. The two most common cancers were prostate and breast, accounting for more than 25 percent of total cancer cases.

Study results show that the use of insulin se
'/>"/>

Contact: Caroline Auger
augerc@ccf.org
216-636-5874
Cleveland Clinic
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Physician Groups Call for Fewer Medical Tests
2. From herd immunity and complacency to group panic: How vaccine scares unfold
3. Study finds significant skull differences between closely linked groups
4. Diabetes Groups Issue New Guidelines on Blood Sugar
5. Small neural focus groups predict anti-smoking ad success
6. Group B streptococcal meningitis has long-term effects on childrens developmental outcomes
7. The Attilio Group’s TAG™-Simply Faster Taps SmartSales To Accelerate Its Expansion Into National Reach
8. Infants cant distinguish between large and small groups
9. Rush joins elite group of institutions with accredited research programs
10. The Casey Group's Sales Navigator Wins 2012 Best Mobility App in the New Jersey Technology Council's Mobile Application Competition
11. Artisan Business Group hosts EB-5 Conference in California
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... ... July 06, 2015 , ... Invitation to Cover: , Most ... a large gap between the unmet health priorities in the region and the ... reduce unnecessary or ineffective treatments or procedures. , This milestone conference, sponsored by ...
(Date:7/6/2015)... (PRWEB) , ... July 06, 2015 , ... ... fat-reduction procedures each year for aesthetic reasons, which is why liposuction regularly ranks ... a particular demographic, however, fat reduction has become more than a way to ...
(Date:7/6/2015)... London, UK (PRWEB) , ... July 06, 2015 , ... ... 5.58 billion in 2014. It is expected to grow at a CAGR of over ... by 2021. , The growth is likely to be mainly spurred by an anticipated ...
(Date:7/6/2015)... ... ... Olive Fertility Centre is proud to announce that Olive medical director Dr. Jason ... department of Family Practice. , “This award is a real honour,” says Dr Hitkari. ... changing so rapidly and we are also developing new models of patient-centred care that ...
(Date:7/6/2015)... ... July 06, 2015 , ... Understanding the new ... ADVOCATE is leading the transition. ADVOCATE, the only 100% radiology, revenue cycle management ... Tips for ICD-10. The ten tips are timely and relevant guidelines to help ...
Breaking Medicine News(10 mins):Health News:Columbia Nursing Nairobi Summit: Setting a Clinical Research Agenda for Africa 2Health News:Learn How CoolSculpting® and Liposuction in Virginia Beach Help Military Members Stay the Course 2Health News:Learn How CoolSculpting® and Liposuction in Virginia Beach Help Military Members Stay the Course 3Health News:APAC Rheumatoid Arthritis Therapeutics Market to Reach Value of USD 6.9 Billion by 2021, Says GBI Research in Its New Report Now Available at MarketPublishers.com 2Health News:Olive Fertility Centre Physician Honoured for Teaching 2Health News:ADVOCATE Takes the Lead to Ensure ICD-10 Success: “Top 10 Tips for ICD-10” 2
... $0.18 Earnings per Share, BILLERICA, Mass., Oct. 23 ... provider of precision technology and,semiconductor systems, today announced financial ... Third quarter revenue was $84.0 million, compared to $73.1 ... for the third quarter of 2006.,Excluding restructuring charges, operating ...
... Aflac Incorporated,today reported its third quarter results. Reflecting ... 5.1% to $3.9,billion during the third quarter of 2007, ... Net earnings were $420 million, or $.85 per diluted,share, ... year ago. Net,earnings included realized investment gains of $1 ...
... With the discovery of suitable molecular targets cellular ... cancer cells comes the perplexing dilemma of where ... and disable those targets. While the possibilities for drug ... and repositories are often problematic or ill-suited for the ...
... clay in unvented kilns could be a significant source ... periods, a new study suggests. , The results came ... the University of Michigan Dioxin Exposure Study, which measured ... River flood plain between Midland and Saginaw. , The ...
... SAN FRANCISCO -- Mayo Clinic today reported promising interim ... combination therapy for patients with recurrent ovarian cancer that ... participants achieved either complete or partial tumor regression from ... Findings from this Phase 2 Consortium (P2C) clinical trial ...
... Disorder Without Disturbing Patients, CHICAGO, Oct. 23 ... measuring airflow by nasal pressure, temperature, and/or carbon,dioxide, ... method is,uncomfortable to some and can potentially disturb ... 73rd annual international scientific assembly,of the American College ...
Cached Medicine News:Health News:GSI Group Reports Third Quarter Results 2Health News:GSI Group Reports Third Quarter Results 3Health News:GSI Group Reports Third Quarter Results 4Health News:GSI Group Reports Third Quarter Results 5Health News:GSI Group Reports Third Quarter Results 6Health News:GSI Group Reports Third Quarter Results 7Health News:GSI Group Reports Third Quarter Results 8Health News:Aflac Incorporated Announces Third Quarter Results, Declares Fourth Quarter Cash Dividend 2Health News:Aflac Incorporated Announces Third Quarter Results, Declares Fourth Quarter Cash Dividend 3Health News:Aflac Incorporated Announces Third Quarter Results, Declares Fourth Quarter Cash Dividend 4Health News:Aflac Incorporated Announces Third Quarter Results, Declares Fourth Quarter Cash Dividend 5Health News:Aflac Incorporated Announces Third Quarter Results, Declares Fourth Quarter Cash Dividend 6Health News:Aflac Incorporated Announces Third Quarter Results, Declares Fourth Quarter Cash Dividend 7Health News:Aflac Incorporated Announces Third Quarter Results, Declares Fourth Quarter Cash Dividend 8Health News:Aflac Incorporated Announces Third Quarter Results, Declares Fourth Quarter Cash Dividend 9Health News:Aflac Incorporated Announces Third Quarter Results, Declares Fourth Quarter Cash Dividend 10Health News:Aflac Incorporated Announces Third Quarter Results, Declares Fourth Quarter Cash Dividend 11Health News:Aflac Incorporated Announces Third Quarter Results, Declares Fourth Quarter Cash Dividend 12Health News:Advances in drug screening: building a better haystack for the needles of tomorrow 2Health News:Advances in drug screening: building a better haystack for the needles of tomorrow 3Health News:Advances in drug screening: building a better haystack for the needles of tomorrow 4Health News:Advances in drug screening: building a better haystack for the needles of tomorrow 5Health News:Advances in drug screening: building a better haystack for the needles of tomorrow 6Health News:Advances in drug screening: building a better haystack for the needles of tomorrow 7Health News:Advances in drug screening: building a better haystack for the needles of tomorrow 8Health News:Firing clay in unvented kilns may be a source of exposure to dioxins 2Health News:Mayo Clinic reports possible new therapy for patients with platinum-resistant ovarian cancer 2Health News:Infrared Imaging for Sleep Apnea Diagnosis Shows Promise 2Health News:Infrared Imaging for Sleep Apnea Diagnosis Shows Promise 3
(Date:7/6/2015)... SOUTH SAN FRANCISCO, Calif. , July 6, 2015 ... leading global pharmaceutical company, and Oculeve, a development-stage medical ... eye disease, today announced that they have entered into ... an all-cash transaction.  Under the terms of the agreement, ... payment and commercialization milestone payments related to Oculeve,s lead ...
(Date:7/6/2015)... , July 6, 2015  OncoSec Medical Inc. ... intratumoral cancer immunotherapies, today announced the appointment of ... of Vice President of Market Development, effective July 6, ... for evaluating, designing, and executing on the company,s market ... "I,m very excited to welcome Joann to the ...
(Date:7/6/2015)... 2015 /PRNewswire/ -- China Nepstar Chain Drugstore Ltd. (NYSE: ... drugstore chain in China based ... that its board of directors has received a preliminary ... Simin Zhang , chairman of the board of directors ... an investment vehicle wholly owned by Mr. Zhang(" Neptunus ...
Breaking Medicine Technology:Allergan to Acquire Oculeve Dry Eye Disease Development Programs 2Allergan to Acquire Oculeve Dry Eye Disease Development Programs 3Allergan to Acquire Oculeve Dry Eye Disease Development Programs 4OncoSec Medical Appoints Joann V. Lofgren as Vice President of Market Development 2OncoSec Medical Appoints Joann V. Lofgren as Vice President of Market Development 3China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 2China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 3China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 4China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 5China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 6
... Md. , June 14 Micromet, Inc. ... updated results from a Phase 1 trial of the ... relapsed non-Hodgkin,s lymphoma (NHL).  A high objective response rate ... adapted schedule, comparable to that previously reported in patients ...
... , June 14 Bayer HealthCare Pharmaceuticals and ... the final analysis of the Phase 3 NExUS ( N ... orafenib) trial evaluating Nexavar® (sorafenib) tablets in patients with advanced ... did not meet its primary endpoint of improving overall survival ...
Cached Medicine Technology:Micromet's Blinatumomab Induces Durable Remissions in Patients with Relapsed Non-Hodgkin's Lymphoma 2Micromet's Blinatumomab Induces Durable Remissions in Patients with Relapsed Non-Hodgkin's Lymphoma 3Micromet's Blinatumomab Induces Durable Remissions in Patients with Relapsed Non-Hodgkin's Lymphoma 4Micromet's Blinatumomab Induces Durable Remissions in Patients with Relapsed Non-Hodgkin's Lymphoma 5Micromet's Blinatumomab Induces Durable Remissions in Patients with Relapsed Non-Hodgkin's Lymphoma 6Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival 2Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival 3Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival 4Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival 5Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival 6Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival 7
This table has adjustable height, square post and adjustable leg. Includes clamps, and standard 1" (2.5 cm) pad....
... versatile model angulates for vascular procedures. ... height of the support leg, which ... or double tee foot. Add up ... and stability. A convenient bracket is ...
The Biomet® CHS is indicated for intertrochanteric, subtrochanteric and basilar neck fractures of the proximal femur....
... trauma procedures. Part of the osi ... table top provides a complete, powered, ... and provides for skin or skeletal ... pinnings; femur, supine or lateral im ...
Medicine Products: